"15110" . "362141" . "1801-1209" . "Indr\u00E1k, Karel" . "P\u0159ed v\u00EDce ne\u017E rokem byl v Evrop\u011B registrov\u00E1n dasatinib (Sprycel) ur\u010Den\u00FD k l\u00E9\u010Db\u011B nemocn\u00FDch s chronickou myeloidn\u00ED leukemi\u00ED (CML) a Philadelphia chromosom (Ph) pozitivn\u00ED akutn\u00ED lymfoblastickou leukemi\u00ED (ALL) rezistentn\u00EDch nebo nesn\u00E1\u0161ej\u00EDch imatinib. Sprycel vyr\u00E1b\u00ED spole\u010Dnost Bristol-Myers Squibb. jde o selektivn\u00ED kompetitivn\u00ED du\u00E1ln\u00ED inhibitor tyrosinov\u00E9 kin\u00E1zy Bcr/Abl a Src kin\u00E1z. In vitro jde zat\u00EDm o nej\u00FA\u010Dinn\u011Bj\u0161\u00ED inhibitor tyrosinov\u00E9 kin\u00E1zy Bcr\u00FAAbl, kter\u00FD je schopen blokovat jak aktivn\u00ED, tak inaktivn\u00ED formu enzymu a je 325x \u00FA\u010Dinn\u011Bj\u0161\u00ED ne\u017E imatinib." . . "Dasatinib - nov\u00E9 informace o d\u00E1vkov\u00E1n\u00ED, \u00FA\u010Dinnosti a bezpe\u010Dnosti" . "Faber, Edgar" . "2"^^ . "Dasatinib - nov\u00E9 informace o d\u00E1vkov\u00E1n\u00ED, \u00FA\u010Dinnosti a bezpe\u010Dnosti"@cs . . "2"^^ . . . "P\u0159ed v\u00EDce ne\u017E rokem byl v Evrop\u011B registrov\u00E1n dasatinib (Sprycel) ur\u010Den\u00FD k l\u00E9\u010Db\u011B nemocn\u00FDch s chronickou myeloidn\u00ED leukemi\u00ED (CML) a Philadelphia chromosom (Ph) pozitivn\u00ED akutn\u00ED lymfoblastickou leukemi\u00ED (ALL) rezistentn\u00EDch nebo nesn\u00E1\u0161ej\u00EDch imatinib. Sprycel vyr\u00E1b\u00ED spole\u010Dnost Bristol-Myers Squibb. jde o selektivn\u00ED kompetitivn\u00ED du\u00E1ln\u00ED inhibitor tyrosinov\u00E9 kin\u00E1zy Bcr/Abl a Src kin\u00E1z. In vitro jde zat\u00EDm o nej\u00FA\u010Dinn\u011Bj\u0161\u00ED inhibitor tyrosinov\u00E9 kin\u00E1zy Bcr\u00FAAbl, kter\u00FD je schopen blokovat jak aktivn\u00ED, tak inaktivn\u00ED formu enzymu a je 325x \u00FA\u010Dinn\u011Bj\u0161\u00ED ne\u017E imatinib."@cs . "RIV/61989592:15110/08:10224415!RIV12-MSM-15110___" . "Farmakoterapie : diagetologie - alergologie - pneumologie - revmatologie" . "4" . "Dasatinib - new information about dosage, efficacy and safety"@en . . "[AB53C9772264]" . "Dasatinib - nov\u00E9 informace o d\u00E1vkov\u00E1n\u00ED, \u00FA\u010Dinnosti a bezpe\u010Dnosti"@cs . "Review focused on new pharmacologic informations about dasatinib and results of recently acomplished clinical studies in Ph-positive hematologic malignancies."@en . "RIV/61989592:15110/08:10224415" . "4" . "CZ - \u010Cesk\u00E1 republika" . . . . . "Dasatinib - nov\u00E9 informace o d\u00E1vkov\u00E1n\u00ED, \u00FA\u010Dinnosti a bezpe\u010Dnosti" . "5"^^ . . . "Dasatinib - new information about dosage, efficacy and safety"@en . . . "Philadelphia chromosome; chronic myeloid leukemia; dasatinib"@en . . . "I" .